Osteonecrosis of the jaw: a rare and devastating side effect of bisphosphonates.

Hdl Handle:
http://hdl.handle.net/10147/126989
Title:
Osteonecrosis of the jaw: a rare and devastating side effect of bisphosphonates.
Authors:
Ryan, P; Saleh, I; Stassen, L F A
Affiliation:
Oral & Maxillofacial Surgery Department, St James's Hospital, Dublin 8, Ireland. ryan.patrick.1@gmail.com
Citation:
Osteonecrosis of the jaw: a rare and devastating side effect of bisphosphonates. 2009, 85 (1010):674-7 Postgrad Med J
Journal:
Postgraduate medical journal
Issue Date:
Dec-2009
URI:
http://hdl.handle.net/10147/126989
DOI:
10.1136/pgmj.2008.076349
PubMed ID:
20075406
Abstract:
Evidence has emerged that bisphosphonate use in cancer patients is associated with osteonecrosis of the jaw. This form of osteonecrosis has been termed bisphosphonate induced osteonecrosis of the jaw (BIONJ). BIONJ is commonly precipitated by a tooth extraction in patients treated with long term, potent, high dose intravenous bisphosphonates for the management of myeloma, breast or prostate cancer. The overall prevalence of BIONJ is about 5% in patients with these malignancies. Current evidence shows that the risk of BIONJ in non-cancerous patients, such as those with osteoporosis, is very low and appears to be comparable with that of the general population. Prescribing physicians need to encourage cancer patients to see their dentists before the initiation of bisphosphonate treatment, and regularly thereafter.
Item Type:
Article
Language:
en
MeSH:
Antineoplastic Agents; Diagnosis, Differential; Diphosphonates; Humans; Jaw Diseases; Neoplasms; Osteonecrosis
ISSN:
1469-0756

Full metadata record

DC FieldValue Language
dc.contributor.authorRyan, Pen
dc.contributor.authorSaleh, Ien
dc.contributor.authorStassen, L F Aen
dc.date.accessioned2011-04-04T12:04:55Z-
dc.date.available2011-04-04T12:04:55Z-
dc.date.issued2009-12-
dc.identifier.citationOsteonecrosis of the jaw: a rare and devastating side effect of bisphosphonates. 2009, 85 (1010):674-7 Postgrad Med Jen
dc.identifier.issn1469-0756-
dc.identifier.pmid20075406-
dc.identifier.doi10.1136/pgmj.2008.076349-
dc.identifier.urihttp://hdl.handle.net/10147/126989-
dc.description.abstractEvidence has emerged that bisphosphonate use in cancer patients is associated with osteonecrosis of the jaw. This form of osteonecrosis has been termed bisphosphonate induced osteonecrosis of the jaw (BIONJ). BIONJ is commonly precipitated by a tooth extraction in patients treated with long term, potent, high dose intravenous bisphosphonates for the management of myeloma, breast or prostate cancer. The overall prevalence of BIONJ is about 5% in patients with these malignancies. Current evidence shows that the risk of BIONJ in non-cancerous patients, such as those with osteoporosis, is very low and appears to be comparable with that of the general population. Prescribing physicians need to encourage cancer patients to see their dentists before the initiation of bisphosphonate treatment, and regularly thereafter.-
dc.language.isoenen
dc.subject.meshAntineoplastic Agents-
dc.subject.meshDiagnosis, Differential-
dc.subject.meshDiphosphonates-
dc.subject.meshHumans-
dc.subject.meshJaw Diseases-
dc.subject.meshNeoplasms-
dc.subject.meshOsteonecrosis-
dc.titleOsteonecrosis of the jaw: a rare and devastating side effect of bisphosphonates.en
dc.typeArticleen
dc.contributor.departmentOral & Maxillofacial Surgery Department, St James's Hospital, Dublin 8, Ireland. ryan.patrick.1@gmail.comen
dc.identifier.journalPostgraduate medical journalen
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.